Showing 941-950 of 9108 results for "".
Allergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focGalderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/videos/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalTaltz Approved, Venus Versa Cleared, Sunbathing Linked to Longevity
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-taltz-approved-venus-versa-cleared-sunbathing-linked-to-longevity/18788/The IL-17 inhibitor Taltz (ixekizumab) from Eli Lilly is approved for adults with plaque psoriasis. Venus Concepts' Venus Versa is cleared for multiple aesthetic indications. Strata Sciences gets FDA clearance for new "Classifier Code" for use with MelaFind. Vitals.com shows that wait times are goinSRT100: Innovating Topical Radiation Therapy for Skin Cancers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/srt100-innovating-topical-radiation-therapy-for-skin-cancers/19041/The United States has become one of the chief areas of non-melanoma as well as melanoma skin cancer. One of the first treatments that was invented by dermatologists has been the use of radiation therapy for skin cancer. George Miller McKee, who is the father of many of the treatments of both melanoDos and don'ts for creating a killer Google Adwords Campaign for your Dermatology Practice
https://practicaldermatology.com/topics/practice-management/dos-and-don-ts-for-creating-a-killer-google-adwords-campaign-for-your-dermatology-practice/18907/Google AdWords could be a great way to promote your practice. But you have to do it right! Learn how to plan and implement a campaign that gets results with reasonable costs.Cynosure Acquires Ellman International
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-cynosure-acquires-ellman-international/19059/Cynosure Acquires Assets of Ellman International, NPF Ramps Up Patient Advocacy, New App Available for Practice, PLUS: Acne Insights.Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosDermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesMayo Clinic Center for Social Media: Optimizing Opportunities
https://practicaldermatology.com/topics/practice-management/mayo-clinic/19359/Experts from the Mayo Clinic Center for Social Media (socialmedia.mayoclinic.org/) offer tips for optimizing social media.Strategizing to Capitalize on Emollients
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/strategizing-to-capitalize-on-emollients/50865/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Dawn Eichenfield, MD, PhD, to discuss “Emollients to Prevent Pediatric Eczema” from JAMA Dermatology.